An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer

E. T. Creagan, Jan Craig Buckner, R. G. Hahn, R. R. Richardson, Daniel J Schaid, J. S. Kovach

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The authors designed a clinical trial to assess the impact of aspirin (ASA) (600 mg four times daily) on the constitutional sequelae of recombinant leukocyte A interferon (IFN-α2A), 20 x 106 U/m2 thrice weekly, in 29 patients with advanced renal cell cancer (RCC). Aspirin provided no meaningful amelioration of side effects compared to our prior experience of IFN-α2A alone. Interestingly, the objective response rate of 34% (10/29) was considerably higher than the 15% recently reported from an aggregate of 344 patients participating in 14 prospective clinical trials. In light of small numbers, subtle selection biases, and the well-recognized hazards of retrospective analyses, currently it is unclear if the apparent therapeutic advantage from ASA plus IFN-α2A reflects chance occurrence or therapeutic potentiation from ASA. A randomized trial is planned to determine if ASA may have enhanced the efficacy of IFN-α2A in patients with advanced RCC.

Original languageEnglish (US)
Pages (from-to)1787-1791
Number of pages5
JournalCancer
Volume61
Issue number9
StatePublished - 1988

Fingerprint

Renal Cell Carcinoma
Interferon-alpha
Aspirin
Clinical Trials
Selection Bias
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer. / Creagan, E. T.; Buckner, Jan Craig; Hahn, R. G.; Richardson, R. R.; Schaid, Daniel J; Kovach, J. S.

In: Cancer, Vol. 61, No. 9, 1988, p. 1787-1791.

Research output: Contribution to journalArticle

Creagan, E. T. ; Buckner, Jan Craig ; Hahn, R. G. ; Richardson, R. R. ; Schaid, Daniel J ; Kovach, J. S. / An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer. In: Cancer. 1988 ; Vol. 61, No. 9. pp. 1787-1791.
@article{de342ed207a74d1f82dab99303a58a06,
title = "An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer",
abstract = "The authors designed a clinical trial to assess the impact of aspirin (ASA) (600 mg four times daily) on the constitutional sequelae of recombinant leukocyte A interferon (IFN-α2A), 20 x 106 U/m2 thrice weekly, in 29 patients with advanced renal cell cancer (RCC). Aspirin provided no meaningful amelioration of side effects compared to our prior experience of IFN-α2A alone. Interestingly, the objective response rate of 34{\%} (10/29) was considerably higher than the 15{\%} recently reported from an aggregate of 344 patients participating in 14 prospective clinical trials. In light of small numbers, subtle selection biases, and the well-recognized hazards of retrospective analyses, currently it is unclear if the apparent therapeutic advantage from ASA plus IFN-α2A reflects chance occurrence or therapeutic potentiation from ASA. A randomized trial is planned to determine if ASA may have enhanced the efficacy of IFN-α2A in patients with advanced RCC.",
author = "Creagan, {E. T.} and Buckner, {Jan Craig} and Hahn, {R. G.} and Richardson, {R. R.} and Schaid, {Daniel J} and Kovach, {J. S.}",
year = "1988",
language = "English (US)",
volume = "61",
pages = "1787--1791",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer

AU - Creagan, E. T.

AU - Buckner, Jan Craig

AU - Hahn, R. G.

AU - Richardson, R. R.

AU - Schaid, Daniel J

AU - Kovach, J. S.

PY - 1988

Y1 - 1988

N2 - The authors designed a clinical trial to assess the impact of aspirin (ASA) (600 mg four times daily) on the constitutional sequelae of recombinant leukocyte A interferon (IFN-α2A), 20 x 106 U/m2 thrice weekly, in 29 patients with advanced renal cell cancer (RCC). Aspirin provided no meaningful amelioration of side effects compared to our prior experience of IFN-α2A alone. Interestingly, the objective response rate of 34% (10/29) was considerably higher than the 15% recently reported from an aggregate of 344 patients participating in 14 prospective clinical trials. In light of small numbers, subtle selection biases, and the well-recognized hazards of retrospective analyses, currently it is unclear if the apparent therapeutic advantage from ASA plus IFN-α2A reflects chance occurrence or therapeutic potentiation from ASA. A randomized trial is planned to determine if ASA may have enhanced the efficacy of IFN-α2A in patients with advanced RCC.

AB - The authors designed a clinical trial to assess the impact of aspirin (ASA) (600 mg four times daily) on the constitutional sequelae of recombinant leukocyte A interferon (IFN-α2A), 20 x 106 U/m2 thrice weekly, in 29 patients with advanced renal cell cancer (RCC). Aspirin provided no meaningful amelioration of side effects compared to our prior experience of IFN-α2A alone. Interestingly, the objective response rate of 34% (10/29) was considerably higher than the 15% recently reported from an aggregate of 344 patients participating in 14 prospective clinical trials. In light of small numbers, subtle selection biases, and the well-recognized hazards of retrospective analyses, currently it is unclear if the apparent therapeutic advantage from ASA plus IFN-α2A reflects chance occurrence or therapeutic potentiation from ASA. A randomized trial is planned to determine if ASA may have enhanced the efficacy of IFN-α2A in patients with advanced RCC.

UR - http://www.scopus.com/inward/record.url?scp=0023906447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023906447&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 1787

EP - 1791

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -